Literature DB >> 2322428

Pharmacovigilance. The French system.

R J Royer1.   

Abstract

The French system of drug surveillance (pharmacovigilance) is a combination of mandatory reporting and intensive hospital surveillance. The Regional Centres are decentralised but coordinated through a national network. An algorithm index is used to assess the relationship between drugs and adverse effects. The adverse reactions alert system is produced by the compilation and analysis of the cases entered in a data bank (8062 in 1988) and by the analysis of queries from general practitioners (20,000 in 1988). The duties of the centres are also to provide information, analyse data and to improve the safe use of drugs.

Mesh:

Year:  1990        PMID: 2322428     DOI: 10.2165/00002018-199000051-00021

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  6 in total

1.  A drug information-ADR collection network: the French system.

Authors:  J Dangoumau; G Lagier; R J Royer
Journal:  Drug Inf J       Date:  1986

2.  [Critical analysis of the adverse effects reported to the Paris-Fernand Widal Drug Monitoring Center in a 2-month period].

Authors:  A Castot; P Carlier; G Lagier; J Elmalem; M Vincens; M Efthymiou
Journal:  Therapie       Date:  1986 Sep-Oct       Impact factor: 2.070

3.  [Information centers on undesirable effects of drugs: also on alerting function].

Authors:  B Bégaud; J C Péré; P Tubert; C Barat; F Haramburu; H Albin
Journal:  Therapie       Date:  1987 Mar-Apr       Impact factor: 2.070

4.  Adverse drug reaction monitoring: doing it the French way.

Authors:  N Moore; M Biour; G Paux; E Loupi; B Begaud; F Boismare; R J Royer
Journal:  Lancet       Date:  1985-11-09       Impact factor: 79.321

5.  [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France].

Authors:  B Bégaud; J C Evreux; J Jouglard; G Lagier
Journal:  Therapie       Date:  1985 Mar-Apr       Impact factor: 2.070

6.  [Mehtod for determination of undesirable effects of drugs].

Authors:  J Dangoumau; J C Evreux; J Jouglard
Journal:  Therapie       Date:  1978 May-Jun       Impact factor: 2.070

  6 in total
  3 in total

1.  The future of pharmacovigilance: a personal view.

Authors:  I Ralph Edwards
Journal:  Eur J Clin Pharmacol       Date:  2008-01-03       Impact factor: 2.953

2.  Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases.

Authors:  D Larrey; T Vial; A Micaleff; G Babany; M Morichau-Beauchant; H Michel; J P Benhamou
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

3.  Large-scale open trials with etodolac (Lodine) in France: an assessment of safety.

Authors:  C L Benhamou
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.